BioCryst Pharmaceuticals BCRX Stock Issued During Period, Value, Stock Options Exercised
Stock Issued During Period, Value, Stock Options Exercised at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised?
- BioCryst Pharmaceuticals (BCRX) reported stock issued during period, value, stock options exercised of $18.37M in Q1 2026.
- How has BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised changed year-over-year?
- BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised increased by 1394.4% year-over-year, from $1.23M to $18.37M.
- What is the long-term trend for BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's stock issued during period, value, stock options exercised has grown at a -13.0% compound annual growth rate (CAGR), from $13.75M to $7.88M.
- What does stock issued during period, value, stock options exercised mean?
- The total cash proceeds received by the company from the exercise of employee or director stock options during the period. This metric highlights the liquidity generated from equity-based compensation plans and the dilution impact on existing shareholders.